Telitacicept Shows Significant Efficacy in IgA Nephropathy: Phase 3 Interim Analysis
A phase 3 interim analysis demonstrates that telitacicept, a dual BAFF/APRIL inhibitor, significantly reduces proteinuria and preserves kidney function in high-risk IgA nephropathy patients, with an acceptable safety profile. These results may alter current management paradigms.